Therapeutic Promise of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor in a Preclinical Model of Colon Carcinogenesis

Clinical and Experimental Pharmacology
doi 10.4172/2161-1459.1000247
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

Effects of the Oral, Direct Thrombin Inhibitor Dabigatran on Five Common Coagulation Assays

Thrombosis and Haemostasis
Hematology
2011English

Oral Antithrombotic Inhibitors: Dabigatran Etexilate, Meeting an Unmet Need?

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2009English

New Oral Antithrombotics: Focus on Dabigatran, an Oral, Reversible Direct Thrombin Inhibitor for the Prevention and Treatment of Venous and Arterial Thromboembolic Disorders

Vascular Health and Risk Management
2012English

Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring

Thrombosis and Haemostasis
Hematology
2017English

An Unusual Side Effect of Dabigatran Etexilate Use - Acute Renal Failure

Eurasian Journal of Emergency Medicine
2019English

New Options With Dabigatran Etexilate in Anticoagulant Therapy

Vascular Health and Risk Management
2010English

Effect of the Oral Thrombin Inhibitor Dabigatran on Allergic Lung Inflammation Induced by Repeated House Dust Mite Administration in Mice

American Journal of Physiology - Lung Cellular and Molecular Physiology
PulmonaryRespiratory MedicinePhysiologyCell Biology
2015English

Rivaroxaban: An Oral Direct Inhibitor of Factor Xa

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2008English

Dabigatran Inhibits Intravitreal Thrombin Activity

Acta Ophthalmologica
MedicineOphthalmology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy